Cancers by Organ
Assembling the drugs disease by disease — lung, breast, colorectal, prostate and more.
Lung Cancer: Matching the Drug to the Tumour's DNA
Two patients, two chest scans that look almost identical — yet one goes home with a single pill and the other starts an intravenous drip of immunotherapy plus chemotherapy. What separated them was not the X-ray but the molecular report on the biopsy. Lung cancer is where oncology stopped treating an organ and started treating a genotype. This chapter assembles everything from the earlier drug-class chapters and shows how the pieces fit one disease.
Breast Cancer: How the Molecular Subtype Chooses the Treatment
Three women, three lumps that look identical on the mammogram, three completely different prescriptions — one leaves with a hormone tablet, one with an antibody infusion, one with chemotherapy. Nothing about the size or the shape sorted them. A pathologist's report on THREE receptors did. Learn to read those three receptors and you can predict, before a single drug is chosen, which road a breast cancer will travel.
Colorectal Cancer: Chemotherapy Backbones and Biomarker-Guided Antibodies
Bowel cancer is where the whole oncology toolbox comes together. A fluoropyrimidine backbone, a platinum or a topoisomerase partner, and then — only if the genetics allow — a targeted antibody. This is a chapter about assembly and about ONE lab result that can switch an entire drug class on or off. Learn to read the biomarkers and the treatment writes itself.
Prostate Cancer: From Watchful Waiting to Castration Resistance
Two men, same diagnosis, opposite advice. One is told his prostate cancer is so slow that the wisest move is careful watching — no drugs at all. The other's cancer has spread to bone and needs the full ladder: androgen blockade, chemotherapy, and radioligands that hunt the tumour by its own surface protein. Prostate cancer is a spectrum, and knowing WHERE a patient sits on it is the whole art of treating it. This chapter assembles the pathway stage by stage.
Skin Cancer and Melanoma: The Immunotherapy and Targeted-Therapy Success Story
A generation ago, metastatic melanoma was a death sentence measured in months. Today the same diagnosis can mean years of life — because we learned to do one of two things: switch off a single mutated signal, or take the brakes off the patient's own immune system. This is the story of how skin cancer became oncology's brightest proof that understanding a tumour's biology changes everything.
Upper GI and Pancreatic Cancer: Gastric, Oesophageal, Liver and Pancreas
Four cancers of the upper gut share a single chemotherapy spine — platinum plus a fluoropyrimidine — yet each hides its own twist: a HER2 test that unlocks a smart antibody in stomach cancer, a brutal three-drug regimen for the pancreas, and an immunotherapy-plus-antibody pair that, after a decade of stalemate, finally moved the needle in liver cancer. Learn the spine once, then learn the twists.
Gynaecological Cancers: Ovarian, Cervical and Endometrial
Three cancers share the same anatomical neighbourhood but almost nothing else. Ovarian cancer hides until it is advanced, then meets platinum chemotherapy and a clever new weapon — a PARP inhibitor that turns a woman's inherited BRCA flaw into the tumour's fatal weakness. Cervical cancer is caused by a virus, which means it is largely PREVENTABLE by a vaccine. Endometrial cancer is often driven by hormones, and its aggressive forms are increasingly opened up by immunotherapy. One organ system, three completely different pharmacological logics.
Bladder and Kidney Cancer: Immunotherapy, Antibody Conjugates and Anti-Angiogenics
One of these cancers is treated by dripping a live tuberculosis vaccine straight into the bladder. Its neighbour, kidney cancer, shrugs off conventional chemotherapy so completely that oncologists gave up on it — and instead learned to starve the tumour's blood supply and set the immune system loose. This is the genitourinary story: an organ system where the classic rule 'cancer means chemotherapy' quietly broke, and something smarter took its place.
Head, Neck and Thyroid Cancer: Chemoradiation, EGFR and Radioiodine
Two cancers share a neighbourhood in the neck but almost nothing else. One is a squamous cancer driven by smoke, alcohol or a virus, fought with radiation, cisplatin and antibodies. The other is a gland so hungry for iodine that we feed it a radioactive form and let it poison itself from within — a targeted therapy invented before the phrase existed. Learn to tell them apart and the whole management falls into place.
Brain Tumours and Sarcomas: Crossing the Barrier and Targeting the Rare
Two of oncology's hardest problems share a theme: getting the right molecule to a place it cannot easily reach. In the brain, the barrier that protects us becomes the tumour's shield, and only a small oral alkylating drug slips through. In the gut, a sarcoma once written off as chemo-resistant was tamed by the very same pill that rewrote leukaemia. One story about crossing a wall; another about hitting a single mutation dead-on.
